To BRAIN Annual Report 2018/19
BRAIN Annual Report 2018/19 with the title ”Pioneering Bioproducts”
Dr. Jürgen Eck, co-founder of BRAIN, long-standing CTO and CEO since 1 August 2015, will hand over his mandate as CEO to Adriaan Moelker, who is to head the Group from 1 February 2020. Mr. Moelker will in future be responsible for the enhanced commercialization of the product and project businesses with the aim of leading the company into its next expansion phase.
As a fully integrated company in the industrial biotechnology area, BRAIN focuses on profitable growth, which opening up new business options as well as combining technological progress with the cost-reducing effects of the volume-scalable product business. Adriaan Moelker brings with him relevant experience from his time at AB Enzymes GmbH in Darmstadt, where he spent nine years as the company’s CEO during its expansionary phase. He spent more than twenty years in industrial biotechnology in leading positions at international companies such as Genencor (now DuPont) and DSM. At BRAIN, he will continue to drive forward the expansion of B2B business, and will also leverage synergies between business units.
“Adriaan Moelker will provide important new momentum for the company’s next expansion.”
Dr. Jürgen Eck will continue to be available to BRAIN as a consultant and, in particular, will provide valuable input for its innovation pipeline. The company’s unique research and development capacities remain an important foundation for its long-term commercial and financial potential.
As one of the leading bioeconomy companies, BRAIN focuses on industrial customers in the chemical, food and cosmetics industries. With Mr. Moelker, the company gains an experienced manager who will purposefully advance the expansion of the product range for these markets and thereby set the course for the future. As a consequence, BRAIN is excellently positioned to exploit growth prospects in international specialty chemicals markets.